| Company Name: | deCODE Genetics, Incorporated | | Ticker Symbol: | DCGN | | | WWW Address: | www.decode.com | | CEO: | Dr. Kari Stefansson, M.D. | | No. of Employees: | 331 | | Common Issue Type: | CS | | Business Description: | A bio-pharmaceutical company, developing and marketing products to improve the treatment, diagnosis and prevention of common diseases.
|
| | | Industry Information: | DIVERSIFIED SERVICES - Research Services [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.035 |  -0.004 | 0.0302 | 0.35 | 0.039 | 0.04 | 0.03 | 3286392 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2.2 | 61.8 | 1.49 | -1.32 | 0.00 | 0.0 | 0.0 | 0.94 - 0.03 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.04 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 2.2 | mil |
| Latest Shares Outstanding | 61.8 | mil |
| Earnings pS (EPS) | -1.32 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 175,514 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 58.8 | mil |
| Float as % of Shares Outstanding | 95.3 | % |
| Foreign Sales | 37 | mil |
| Domestic Sales | 21 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 57.20 | % |
| Research & Devlopment (R&D) as % of Revenue | 42.40 | % |
| Gross Profit Margin | 31.9 | % |
| EBITDA Margin | -67.8 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | -88.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 243.1 | % |
| Current Ratio | 0.4 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | -0.32 | $ |
| Cash pS | 0.06 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -4.17 | $ |
| Cash Flow pS | -0.85 | $ |
| Free Cash Flow pS | -0.44 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.01 | |
| Price/Cash Flow | 0.0 | |
| Price/Free Cash Flow | -0.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -18.6 | 80 | 54,632 | 57,588 |
| 4 Weeks | 0.35 | 0.03 | 0.33 | -89.4 | 10 | 33,708 | 573,030 |
| 13 Weeks | 0.66 | 0.03 | 0.55 | -93.6 | 6 | 12,861 | 784,520 |
| 26 Weeks | 0.94 | 0.03 | 0.37 | -90.5 | 8 | 11,408 | 1,426,040 |
| 52 Weeks | 0.94 | 0.03 | 0.24 | -85.4 | 12 | 8,254 | 2,055,335 |
| YTD | 0.94 | 0.03 | - | -81.1 | 15 | 8,932 | 2,027,642 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.04 | 0.11 | 0.34 | 0.43 | 0.38 | 1.49 | 1.37 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 2.25 | 9.7 | 4.94 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 11.44 | NA | -27.41 |
| R&D | -6.79 | NA | -22.82 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -74.6 | -76.7 | 43.8 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.31 | 0.09 | 0.25 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -14.49 |
| Current Ratio | 0.6 |
| Quick Ratio (Acid Test) | 0.4 |
| Liquidity Ratio (Cash) | 0.13 |
| Receivables Turnover | 6.2 |
| Average Collection Period | 58 |
| Working Capital/Equity | 4.9 |
| Working Capital pS | -0.18 |
| Cash-Flow pS | -1.14 |
| Free Cash-Flow pS | -0.91 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -3.71 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 394.2 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1,449.7 |
| LT Debt/Total Liabilities | 80.9 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 35.40 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.94 |
| Tobin's Q Ratio | 0.03 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -6.86 |
| Enterprise Value (EV)/Free Cash Flow | -1.00 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.01 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | 0.0 |
| Price/Free Cash Flow Ratio - LTM | -0.1 |
| Price/Sales Ratio | 0.05 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 3.88 |
| Current Liabilities pS | 0.46 |
| Tangible Book Value pS - LTM | -4.17 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.30 |
| Cash pS - LTM | 0.06 |
| Cash Flow pS - LTM | -0.85 |
| Free Cash Flow pS - LTM | -0.44 |
| Earnings pS (EPS) | -1.32 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -96.94 |
| Free Cash Flow Margin 5YEAR AVG | -139.14 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.26 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 3.15 |
| Return on Capital Invested (ROCI) | -438.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -57.8 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | -107.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | -40.5 |
| Gross Profit Margin | 31.9 |
| Gross Profit Margin - 5YEAR AVRG. | 22.9 |
| EBITDA Margin - LTM | -67.8 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 57 |
| Revenue per Employee | 175,514 |
| Net Income per Employee | -244,553 |
| Average Collection Period | 57 |
| Receivables Turnover | 6.2 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 21.00 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | -5.34 |
| Fixed Assets Turnover | 1.01 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 15.70 |
| Revenue per $ Plant | 2.82 |
| Revenue per $ Common Equity | -0.26 |
| Revenue per $ Capital Invested | 3.15 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 48.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 53.7 |
| Research & Devlopment (R&D) as % of Revenue | 52.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 52.9 |
|
|  
|
| |
 |  |